Physician profile
Wilson Bernales
NPI 1508824467
$23,306.40
in general payments reported to CMS, 2019-2025
71 companies · $3,604 in 2025
The $3,604 reported for 2025 was more than what 97% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,419 · 2020: $1,180 · 2021: $5,053 · 2022: $1,122 · 2023: $3,300 · 2024: $4,627 · 2025: $3,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,489.22 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,686.72 | 2019-2025 | Farxiga, Tezspire, Fasenra |
| Abbvie INC. | $1,889.49 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $1,654.91 | 2019-2025 | Arexvy, Ojjaara |
| Biohaven Pharmaceuticals, INC. | $1,438.09 | 2021 | |
| Grifols USA, LLC | $1,224.67 | 2019-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $1,219.25 | 2019-2025 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $1,062.79 | 2020-2025 | Glassia |
| Gilead Sciences, INC. | $948.26 | 2021-2024 | Epclusa, Descovy, Livdelzi |
| Abbott Laboratories | $826.68 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Amgen INC. | $821.53 | 2019-2025 | Tavneos, Tezspire, Otezla |
| Viiv Healthcare Company | $650.43 | 2021-2024 | Apretude, Dovato |
| Janssen Pharmaceuticals, INC | $459.53 | 2019-2021 | |
| Novo Nordisk INC | $436.67 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Avadel Cns Pharmaceuticals, LLC | $368.85 | 2024-2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $367.65 | 2020-2024 | Jardiance |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilson Bernales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.